Ammar Khalifa, MD
Internal Medicine · Overland Park, KSNPI 1780677948
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 476 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 10.2% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 476 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$865
- Abbott$735
- AbbVie$612
- Boehringer Ingelheim$494
- Novo Nordisk$460
- Bayer$421
- plus $5K from 54 others
What the payments were for
- Food & beverage$8,484100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,484 in reported general payments places this provider in the 95th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,247 | $429,175 |
| JardianceEmpagliflozin | 243 | $112,186 |
| OzempicSemaglutide | 94 | $101,342 |
| XareltoRivaroxaban | 196 | $78,380 |
| MyrbetriqMirabegron | 215 | $63,179 |
| JanuviaSitagliptin Phosphate | 145 | $61,333 |
| TrulicityDulaglutide | 37 | $44,155 |
| MounjaroTirzepatide | 21 | $23,244 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 57 | $20,836 |
| SantylCollagenase Clostridium Hist. | 55 | $20,716 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $20,380 |
| EntrestoSacubitril/Valsartan | 38 | $19,249 |
| RexultiBrexpiprazole | 20 | $19,069 |
| LinzessLinaclotide | 21 | $15,681 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $13,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $183 | $429,1751,247 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Glyxambi, Combivent Respimat | $494 | $138,458302 claims |
| Novo NordiskOzempic | $460 | $101,34294 claims |
| Johnson & JohnsonXarelto | $273 | $78,380196 claims |
| MerckJanuvia, Janumet | $207 | $75,227168 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $865 | $67,39958 claims |
| AbbVieLinzess, Lumigan, Restasis | $612 | $30,81268 claims |
| GSKBreo Ellipta | $26 | $20,38045 claims |
| NovartisEntresto | $339 | $19,24938 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $121 | $19,06920 claims |
| AstraZenecaFarxiga, Symbicort | $260 | $14,62456 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $68 | $12,8471,183 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Overland Park
- Herbert WaxmanOverland Park$82K
- Shadrach SmithOverland Park$27K
- David EdalatiOverland Park$21K
- Jennifer BrownOverland Park$9K
- Bruce SalvaggioOverland Park$8K
- Vijaya SamuelOverland Park$8K
- Shazia Walijan MunirOverland Park$7K
- Matthew SwanOverland Park$7K
- Victoria WeaverOverland Park$7K
- Michelle LesterOverland Park$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.